Adaptimmune Therapeutics plc (473A) — Cash Flow Reinvestment Rate

Latest as of June 2024: 0.03x

Adaptimmune Therapeutics plc (473A) has a Cash Flow Reinvestment Rate of 0.03x as of June 2024, reinvesting €1.50 Million (capex €754.00K plus investments €-743.00K) from operating cash flow of €47.40 Million. See Adaptimmune Therapeutics plc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

0.03x

(Capex + Investments) / Operating CF

Total Reinvested

€1.50 Million

Capex + Investments

Operating Cash Flow

€47.40 Million

EUR

Capital Expenditures

€754.00K

EUR

Adaptimmune Therapeutics plc Cash Flow Reinvestment Rate (2021–2021)

Historical reinvestment intensity for Adaptimmune Therapeutics plc across 1 annual periods. For the full cash flow conversion analysis, see Adaptimmune Therapeutics plc (473A) cash conversion ratio.

Annual Cash Flow Reinvestment Rate for Adaptimmune Therapeutics plc (2021–2021)

Year-by-year capital reinvestment analysis for Adaptimmune Therapeutics plc. See Adaptimmune Therapeutics plc (473A) flexibility index to measure the company's free cash flow as a share of total liabilities.

Year	Reinvestment Rate	Total Reinvested (EUR)	Operating CF	Capex	YoY Change
2021	8.68x	€93.16 Million	€10.73 Million	€8.57 Million	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow